Company / Operating Cash Flow per Share
United Therapeutics Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
$34.82
FY2025
5-year range
$13.44 / $34.82
FY2021-FY2025
Trend
+23.4%
vs FY2024
Sector context
#3 of 212
Health Care
What the data says
Among 212 Health Care companies, United Therapeutics is in the top 1% for operating cash flow per share. Operating Cash Flow per Share has increased for 4 consecutive years, from $13.44 in FY2021 to $34.82 in FY2025.
Based on SEC 10-K filings.
34.82 in FY2025 with a 5-year CAGR of +15.1%. Ranks 3rd among 212 companies in Health Care.
Improved from $21.25 to $34.82 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- +25.1%
- 5-Year CAGR
- +15.1%
- 10-Year CAGR
- -
Sector benchmark
+336.5% above sector average
Key checks
Key Insights
- United Therapeutics's operating cash flow per share has grown for 4 consecutive years.
- In FY2025, operating cash flow per share increased 23.4% year-over-year.
- Ranks #3 out of 212 companies in the Health Care sector.
- Lowest operating cash flow per share in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $34.82 | +23.4% |
| FY2024 | $28.21 | +32.8% |
| FY2023 | $21.25 | +19.4% |
| FY2022 | $17.79 | +32.4% |
| FY2021 | $13.44 | -21.9% |
| FY2020 | $17.22 | +463.3% |
| FY2019 | -$4.74 | -126.3% |
| FY2018 | $18.00 | +102.1% |
| FY2017 | $8.91 | -36.7% |
| FY2016 | $14.06 | +73.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026